USANA Health Sciences, Inc. (NYSE:USNA) Major Shareholder Myron W. Wentz Sells 3,700 Shares

USANA Health Sciences, Inc. (NYSE:USNAGet Free Report) major shareholder Myron W. Wentz sold 3,700 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $48.61, for a total transaction of $179,857.00. Following the sale, the insider now owns 7,880,043 shares in the company, valued at approximately $383,048,890.23. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

USANA Health Sciences Stock Down 1.7 %

USANA Health Sciences stock opened at $45.39 on Friday. The stock has a market cap of $864.68 million, a PE ratio of 14.14, a P/E/G ratio of 1.39 and a beta of 0.93. USANA Health Sciences, Inc. has a 12-month low of $41.45 and a 12-month high of $69.60. The business’s 50-day moving average price is $46.13 and its two-hundred day moving average price is $48.24.

USANA Health Sciences (NYSE:USNAGet Free Report) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.17. The company had revenue of $227.80 million for the quarter, compared to analyst estimates of $223.27 million. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. As a group, analysts expect that USANA Health Sciences, Inc. will post 2.78 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Hsbc Holdings PLC bought a new stake in USANA Health Sciences during the 3rd quarter worth $570,000. Pacer Advisors Inc. boosted its stake in shares of USANA Health Sciences by 75.7% during the fourth quarter. Pacer Advisors Inc. now owns 337,371 shares of the company’s stock valued at $18,083,000 after purchasing an additional 145,373 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of USANA Health Sciences by 2.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 90,659 shares of the company’s stock worth $5,314,000 after purchasing an additional 2,168 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of USANA Health Sciences by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock valued at $36,323,000 after buying an additional 21,524 shares during the period. Finally, Exchange Traded Concepts LLC raised its holdings in USANA Health Sciences by 7.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 16,534 shares of the company’s stock valued at $886,000 after buying an additional 1,162 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, DA Davidson reduced their target price on USANA Health Sciences from $48.00 to $46.00 and set a “neutral” rating on the stock in a report on Tuesday, May 7th.

Get Our Latest Research Report on USANA Health Sciences

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

Further Reading

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.